Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for TFBS Bioscience Inc. (6939:TWSE), powered by AI.
TFBS Bioscience Inc. is currently trading at $20.20. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for TFBS Bioscience Inc. on Alpha Lenz.
View TFBS Bioscience Inc.'s valuation metrics on Alpha Lenz.
“TFBS Bioscience Inc.'s ROE is -6.2%. Explore profitability and growth together.”
Ask for details →TFBS Bioscience Inc. is a contract research organization specializing in advanced biological testing and viral vector manufacturing services. Established in 2016 and headquartered in New Taipei City, Taiwan, the company serves the biotechnology and pharmaceutical sectors by supporting the development and production needs of cell and gene therapy products, vaccines, and other biologics. TFBS Bioscience offers a comprehensive suite of services, including biosafety analysis, product release testing, core laboratory support, animal studies, and both good manufacturing practice (GMP) and research-grade manufacturing of viral vectors such as AAV, lentivirus, retrovirus, and adenovirus. The company is recognized for being the first in Taiwan to establish a dedicated facility for viral vector contract development and manufacturing, providing fully integrated, end-to-end development solutions that meet both clinical trial and commercial production requirements. With a strong foundation in regulatory compliance and technical expertise rooted in Taiwan’s leading research institutions, TFBS Bioscience plays a vital role in accelerating the development, safety validation, and market entry of innovative biopharmaceutical therapies across the Asia-Pacific region.
“TFBS Bioscience Inc.'s ROE is -6.2%. Explore profitability and growth together.”
Ask for details →TFBS Bioscience Inc. (ticker: 6939) is a company listed on TWSE in the Healthcare sector (Diagnostics & Research).
The current price is 20.2 with a P/E ratio of -x and P/B of -x.
ROE is -6.22% and operating margin is -40.39%. Annual revenue is $193M.